mmpl3

SQ109 (NSC 722041) is an ethambutol (EMB) derivative and a specific inhibitor of MmpL3, exhibiting potent anti-Mycobacterium tuberculosis activity. SQ109 effectively inhibits the adult stage of the parasite Trypanosoma and kills cells, with an IC50 of 50 ± 8 nM. SQ109 can be used in tuberculosis and antiparasitic research.

AU1235 is a Mycobacterium tuberculosis inhibitor.

C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3).

NITD-349 is an inhibitor of MmpL3. It shows highly potent anti-mycobacterial activity with MIC50 of 23 nM against virulent Mycobacterium tuberculosis H37Rv.

BM212 is an antimycobacterial compound.It inhibits the growth of laboratory and clinical isolate M. tuberculosis strains.

MmpL3-IN-1, also known as compound 32, is a highly effective inhibitor of Mycobacterial membrane protein large 3 (MmpL3). With an anti-tuberculosis activity exhibiting a minimum inhibitory concentration (MIC) of less than 0.016 μg/mL in M. tuberculosis, MmpL3-IN-1 is a valuable compound for research on drug-resistant tuberculosis [1].

MmpL3-IN-3 (Compound 12), an MmpL3 inhibitor, exhibits potent anti-tuberculosis activity with a minimum inhibitory concentration (MIC) of 0.1 μM against H37Rv and demonstrates good metabolic stability in mouse liver microsomes. This compound is valuable for anti-tubercular research [1].

MmpL3-IN-2, an inhibitor targeting MmpL3, exhibits low cytotoxicity and moderate metabolic stability, making it suitable for tuberculosis research [1].

MSU-44147 is a small-molecule inhibitor that targets the membrane transport protein MmpL3 in Mycobacterium abscessus. MSU-44147 exhibits selective anti-mycobacterial activity and low cytotoxicity toward eukaryotic cells. By inhibiting MmpL3-mediated lipid transport, MSU-44147 disrupts cell wall synthesis and biofilm formation, and exhibits bactericidal activity against intracellular bacteria; simultaneously, it produces additive or synergistic effects when used in combination with various antibiotics.

BM635 is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 hydrochloride is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 mesylate is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

Antitubercular agent-33 is an effective MmpL3 inhibitor (MIC = 0.5 μM). It disrupts M. tuberculosis cell wall integrity by blocking mycolic acid transport, used for anti-TB drug development.

MSU-43557 is an inhibitor and antibacterial agent targeting Mycobacterium abscessus MmpL3, featuring low eukaryotic cytotoxicity, narrow antibacterial spectrum and low drug resistance incidence. It inhibits MmpL3, reduces the content of trehalose dimycolate, interferes with biofilm formation and reduces bacterial activity, and also exerts bactericidal effects on intracellular Mycobacterium abscessus. Combined with antibiotics, it produces additive or synergistic effects, suitable for research on multidrug-resistant strains and related infections of Mycobacterium abscessus.

GSK366A is an anti-TB agent against Mycobacterium bovis BCG and Mycobacterium tuberculosis, targeting MmpL3 and inhibiting EchA6.

BM635 hydrochloride is an MmpL3 inhibitor that exhibits significant anti-Divergent bacteriophage effects, inhibiting the binding of Divergent bacteriophage H37Rv (MIC50: 0.08 μM). Exposure to BM635 hydrochloride was doubled in vivo compared to free BM635.

BM635 mesylate, an inhibitor of MmpL3, exhibited significant anti-Divergent bacterium effects, inhibiting and binding Divergent bacterium H37Rv with an MIC50 value of 0.6 μM. BM635 mesylate was able to significantly increase bioavailability compared to free BM635.

IC2418 is an MmpL3 inhibitor, being active against drug-resistant Mycobacterium tuberculosis.

Tuberculosis inhibitor 12 is a potent MmpL3 protein inhibitor (MIC = 0.25 μM). It blocks mycolic acid transport to disrupt cell wall integrity, used for anti-tuberculosis drug development research.

MSU-43085, an orally active MmpL3 inhibitor targeting Mycobacterium tuberculosis (Mtb), demonstrates effective inhibition of Mtb in an acute murine tuberculosis infection model. This compound is applicable in tuberculosis research [1].